“We do not anticipate supply constraints for the U.S. launch of Mounjaro and we will monitor U.S. uptake to determine the appropriate timing for OUS launches.”

In context

“the same broad open access which we achieved for Trulicity. As we remain focused on strong execution, we're encouraged by the prescription trends from Mounjaro, including the most recent IQVIA data, shown over 20% share of market for new-to-brand prescriptions in the Type 2 diabetes injectable incretin class. We are also pleased to see that total Lilly-Ntabren share in the type 2 diabetes injectable incurring class has grown nearly 12 percentage points since the launch of Mounjaro. Given the heavy utilization of co-pay cards as we build out access for Mounjaro, prescription trends will likely provide a more accurate measure of launch uptake than net sales over the next few quarters. We are pleased with the initial uptake of Mounjaro which is at the high end of our contemplated scenarios. We do not anticipate supply constraints for the U.S. launch of Mounjaro and we will monitor U.S. uptake to determine the appropriate timing for OUS launches. As a reminder, over the last several years, we have made significant investments to grow our global manufacturing capacity to support Manja volume, including our new RTP side in North Carolina which will come online in 2023. On Slide 12, we provide an update on capital allocation. For the first half of the year, we invested $4.5 billion to drive our future growth through a combination of R&D expenditures, business development outlays and capital investments. In addition, we returned approximately $1.8 billion to shareholders in dividends and repurchased $1.5 billion in stock. Our capital allocation priorities remain consistent as we continue to fund our key marketed products and expected new launches, invest in our pipeline, pursue opportunities for external innovation to augment our futu”